Novartis (NOVN) is cutting 1,960 jobs in the U.S. The announcement comes as the company anticipates losing patent exclusivity on the drug Diovan in September 2012. The cost cutting measure also follows disappointing trials of Tekturna, another hypertension medication made by Novartis.
The company terminated trials of Tekturna after the pill caused complications for diabetes patients. Analysts say that growth will likely struggle in light of the charges the company is taking on Tekturna and generic competition for Diovan.
Basel, Switzerland-based Novartis has been cutting expenses since Joe Jimenez became chief executive officer in February 2010. The latest layoffs are the third time Novartis has announced job cuts in the past 14 months. The company announced 1,400 layoffs in November 2010 and 200 more in October 2011.Of the 1,960 job cuts planned for the current year, 1,630 will be from the company's sales division. The reductions will save the company an estimated $450 million by 2013.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV